MMA Embolization for Refractory Chronic Migraine

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Study ID
NCT06735833
Status
Recruiting

Conditions

  • Migraine Disorders

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Middle Meningeal Artery embolization — DEVICE
    Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system

Study Details

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

Key Dates

Start date
Apr 23, 2025
Status verified
Jun 2026
Primary completion
Dec 25, 2026
Completion
Jul 31, 2029

Study Design

Enrollment
70 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY

Primary Outcome Measure

Change from baseline, in number of migraine days [ Time Frame: over 28 days post study intervention ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Barrow Neurological Institute at St. Joseph's HospitalPhoenixArizona85013-
John Muir Physician Network Clin. Research CenterWalnut CreekCalifornia94598-
Hartford HospitalHartfordConnecticut06032-
University of Buffalo Medical CenterBuffaloNew York14203-
Mount SinaiNew YorkNew York10029-
Stony Brook University Medical CenterStony BrookNew York11794-
Thomas Jefferson University HospitalPhiladelphiaPennsylvania19107-
Semmes Murphey FoundationMemphisTennessee38120-
West Virginia UniversityMorgantownWest Virginia26506-

Find similar trials in Phoenix, AZ

Related Studies